These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25759214)

  • 21. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA stability and antibody production in CHO cells: improvement through gene optimization.
    Hung F; Deng L; Ravnikar P; Condon R; Li B; Do L; Saha D; Tsao YS; Merchant A; Liu Z; Shi S
    Biotechnol J; 2010 Apr; 5(4):393-401. PubMed ID: 20222103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
    Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
    MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based engineering of a monoclonal antibody for improved solubility.
    Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
    Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches.
    Casaz P; Boucher E; Wollacott R; Pierce BG; Rivera R; Sedic M; Ozturk S; Thomas WD; Wang Y
    MAbs; 2014; 6(6):1533-9. PubMed ID: 25484044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.
    Du Q; Damschroder M; Pabst TM; Hunter AK; Wang WK; Luo H
    MAbs; 2019; 11(4):789-802. PubMed ID: 30913985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
    Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
    Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
    Lavoisier A; Schlaeppi JM
    MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.
    Chow CK; Allan BW; Chai Q; Atwell S; Lu J
    Mol Pharm; 2016 Mar; 13(3):915-23. PubMed ID: 26849155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods.
    Chae H; Cho S; Jeong M; Kwon K; Choi D; Lee J; Nam W; Hong J; Lee J; Yoon S; Hong H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Guided Design of Antibodies.
    Caravella JA; Wang D; Glaser SM; Lugovskoy A
    Curr Comput Aided Drug Des; 2010; 6(2):128-38. PubMed ID: 26845329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.